Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29339065 | 0.96 | MAPT (0.50) | KDM4EMAPTALDH1A1TDP1APEX1 | |
| SCHEMBL718877 | 0.84 | MAPT (0.47) | KDM4EMAPTALDH1A1TDP1APEX1 | |
| SCHEMBL29860001 | 0.81 | KDM4E (0.44) | KDM4EMAPTALDH1A1TDP1APEX1 | |
| SCHEMBL10699834 | 0.78 | MAPT (0.42) | KDM4EMAPTALDH1A1TDP1APEX1 | |
| SCHEMBL14511179 | 0.77 | MAPT (0.68) | KDM4EMAPTALDH1A1TDP1APEX1 | |
| SCHEMBL29859868 | 0.76 | DRD2 (0.47) | KDM4EMAPTALDH1A1TDP1APEX1 | |
| SCHEMBL29859646 | 0.76 | DRD2 (0.47) | KDM4EMAPTALDH1A1TDP1APEX1 | |
| SCHEMBL12445185 | 0.74 | MAPT (0.65) | KDM4EMAPTALDH1A1TDP1APEX1 | |
| SCHEMBL29859765 | 0.73 | KDM4E (0.49) | KDM4EMAPTALDH1A1TDP1APEX1 | |
| SCHEMBL30592549 | 0.73 | DRD2 (0.49) | KDM4EMAPTALDH1A1TDP1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11024815-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| EP-3254317-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| WO-2016124304-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | WO | disclosed |
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK1, CDK3, CDK13 | KDM4E 990/4885MAPT 447/4885ALDH1A1 3914/4885 |
| US-11024815-B2 | Metal complexes | EXOC4, EXOC3, TIMCC | KDM4E 3894/4885MAPT 2450/4885ALDH1A1 2742/4885 |
| US-20180026209-A1 | Metal Complexes | AP3M1, AP2M1, SOD1 | KDM4E 3864/4885MAPT 639/4885ALDH1A1 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.